LONDON, January 22, 2013 /PRNewswire/ --
The medical appliances and equipment industry faced its fair share of challenges during the recession, as procedural volume in some cases was reduced due to the economic situation in the U.S. and Europe. Analysts from our services research team completed in-depth analysis on Boston Scientific Corporation (NYSE: BSX) and Medtronic Inc. (NYSE: MDT). These free reports are available at
Competition also crimped margins for several companies, leading to lower sales and profits. However, with the recession in the rear view mirror, the outlook for the industry and companies such as Boston Scientific and Medtronic is positive. Now that companies have been afforded some breathing room, they are focusing their attentions on bringing new products to market and growing their international footprint. Download the free report on Scientific by signing up now at
Both Boston Scientific and Medtronic [Free Report on MDT] have been looking to new products to grow their top- and bottom-lines, and both have recently been involved with paroxysmal atrial fibrillation. Atrial fibrillation affects around 15 million people globally, and can cause serious health problems such as strokes and heart failure.
In the case of Boston Scientific, the company newly announced that the first patient has been treated in its ZERO AF clinical trial. The results of the trial are anticipated to be used to back up an FDA regulatory submission for a paroxysmal atrial fibrillation indication.
Medtronic has also been busy, recently stating that the FDA has cleared the FlexCath Advance (TM) Steerable Sheath, an improvement to the Arctic Front Advance (TM) Cryoballon System. The new sheath will make it easier to reach inferior veins of the heart when delivering and positioning the cryoballoon catheter in the left atrium to treat paroxysmal atrial fibrillation.
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at
Copyright©2012 PR Newswire.
All rights reserved